Table 1.
Concurrent Chemotherapy and Radiation Therapy for Localized Adenocarcinoma of the Prostate: Comparison of Three Trials
| Trial | N | Therapy | Feasibility | GI Toxicity | GU Toxicity | Hematologic Toxicity |
|---|---|---|---|---|---|---|
| Kumar et al. 200320 | 22 | Docetaxel + 70.2 | 100% | Grade II: 36% | Grade II: 36% | Grade II: 0% |
| Gy (pelvis) | Grade III: 10% | Grade III: 0% | Grade III: 0 | |||
| Late grade II: 10% | ||||||
| Khil et al.199722 | 65 | EV + 65–70 Gy | 70% | Grade II: 57% | Grade II: 72% | Grade III: 1% |
| Grade III: 1% | ||||||
| Grade IV: 1% | ||||||
| Zelefsky et al.200021 | 27 | EV → 75.6 | 85% | Grade II: 35% | Grade II: 48% | Grade III: 10% |
| Gy (p.o.) + EV | Late grade II: 20% | Late grade III: 12% | Liver grade III: 10% |
EV, estramustine phoshate and vinblastine; GI, gastrointestinal; GU, genitourinary; p.o., prostate only